Influence of 5-aminoisoquinolin-1-one (5-AIQ) on neutrophil chemiluminescence in rats with transient and prolonged focal cerebral ischemia and after reperfusion
- PMID: 19212013
Influence of 5-aminoisoquinolin-1-one (5-AIQ) on neutrophil chemiluminescence in rats with transient and prolonged focal cerebral ischemia and after reperfusion
Abstract
Stimulation of neutrophils by different factors increases their oxidative activity and the free radicals produced can report on the degree of activation. Poly(adenosine 5'-diphosphate ribose)polymerase-1 (PARP-1), a nuclear enzyme activated by strand breaks in DNA, plays an important role in the tissue injury associated with ischaemia-reperfusion injury and inflammation. 5-aminoisoquinolin-1-one (5-AIQ) is a potent inhibitor of PARP-1 activity in vitro and in vivo in rats. Acute (80 min) and prolonged (24h) focal cerebral ischaemia was induced in rats by obstruction of the median cerebral artery, with or without reperfusion, with or without administration of 5-AIQ. The oxidative activity of neutrophils was measured by chemiluminescence. Administration of 5-AIQ.HCl (3.0 mg kg(-1) b.w. - i.v.) caused a significant decrease in the oxidative activity of neutrophils in the group which had experienced chronic ischaemia for 24h but had no significant effect in the group which had received 80 min ischaemia, when compared to the control group. Increase of the oxidative activity of neutrophils was confirmed in rats with prolonged cerebral ischaemia, followed by reperfusion. 5-AIQ probably may decrease this activity through inhibition of PARP-1 in focus of local ischaemia as well as hence lowering the expression of inflammatory mediators by activated neutrophils.
Similar articles
-
5-Aminoisoquinolinone reduces renal injury and dysfunction caused by experimental ischemia/reperfusion.Kidney Int. 2004 Feb;65(2):499-509. doi: 10.1111/j.1523-1755.2004.00415.x. Kidney Int. 2004. PMID: 14717920
-
Beneficial effects of 5-aminoisoquinolinone, a novel, potent, water-soluble, inhibitor of poly (ADP-ribose) polymerase, in a rat model of splanchnic artery occlusion and reperfusion.Eur J Pharmacol. 2004 May 25;492(2-3):203-10. doi: 10.1016/j.ejphar.2004.03.033. Eur J Pharmacol. 2004. PMID: 15178366
-
Inhibitors of poly (ADP-ribose) polymerase ameliorate myocardial reperfusion injury by modulation of activator protein-1 and neutrophil infiltration.Shock. 2005 Mar;23(3):233-8. Shock. 2005. PMID: 15718920
-
5-Aminoisoquinolin-1-one (5-AIQ), a Water-Soluble Inhibitor of the Poly(ADP-Ribose)Polymerases (PARPs).Curr Med Chem. 2015;22(33):3807-29. doi: 10.2174/0929867322666151002110602. Curr Med Chem. 2015. PMID: 26429070 Review.
-
PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases.Free Radic Biol Med. 2009 Jul 1;47(1):13-26. doi: 10.1016/j.freeradbiomed.2009.04.008. Epub 2009 Apr 10. Free Radic Biol Med. 2009. PMID: 19362586 Review.
Cited by
-
Neuroprotective Effects of Poly(ADP-ribose)polymerase Inhibitor Olaparib in Transient Cerebral Ischemia.Neurochem Res. 2016 Jul;41(7):1516-26. doi: 10.1007/s11064-016-1864-6. Epub 2016 Feb 11. Neurochem Res. 2016. PMID: 26869042
-
The potential of PARP inhibitors in neuro-oncology.CNS Oncol. 2012 Sep;1(1):85-97. doi: 10.2217/cns.12.13. CNS Oncol. 2012. PMID: 25054302 Free PMC article. Review.
-
Antidepressant-Like Actions of Inhibitors of Poly(ADP-Ribose) Polymerase in Rodent Models.Int J Neuropsychopharmacol. 2017 Dec 1;20(12):994-1004. doi: 10.1093/ijnp/pyx068. Int J Neuropsychopharmacol. 2017. PMID: 29016792 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous